Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Journal: Nature Medicine

Published: 2020-10-05

DOI: 10.1038/s41591-020-1081-3

Affiliations: 6

Authors: 16

Go to article
Institutions Share
Medical College of Wisconsin (MCW), United States of America (USA) 0.63
Lentigen Corporation, United States of America (USA) 0.33
University of Washington (UW), United States of America (USA) 0.02
Seattle Children's Research Institute, United States of America (USA) 0.02

Return